Amgen Inc. (AMGN) 

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Investors who purchased Amgen securities are encouraged to obtain additional information and assist the investigation.      

 

The investigation concerns whether Amgen and certain of its officers and/or directors have violated federal securities laws.

 

On April 27, 2022, Amgen disclosed in its first quarter 2022 earnings release that “[o]n April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service (‘IRS’)] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company’s entities in the United States and the U.S. territory of Puerto Rico” which “seeks to increase Amgen’s U.S. taxable income for the 2013-2015 period  by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest.”  The Company also disclosed that the IRS “notice proposes penalties of approximately $2 billion.”  On this news, Amgen’s stock price fell sharply during intraday trading on April 28, 2022.

 

If you are aware of any facts relating to this investigation or purchased Amgen shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.